The 58% ORR in first-line PDAC is well above historical chemo benchmarks (~30-35%), suggesting potential for accelerated approval. Monitor upcoming Phase 3 readouts and any FDA breakthrough designation decisions. Despite recent insider selling, the clinical signal is strong enough to justify near-term upside.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $141.50entry
- T+1 · 7mo ago −4.96%α −4.57% · $134.48
- T+5 · 7mo ago −0.49%α −0.55% · $140.80
- T+20 · 6mo ago +4.10%α +0.93% · $147.30
- T+60 · 4mo ago +31.56%α +26.78% · $186.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing a 58% confirmed ORR in combination with chemotherapy and 47% in monotherapy, with manageable safety profiles. These results support ongoing Phase 3 trials in frontline PDAC, a high-unmet need indication with ~3% five-year survival.
Key Facts
- Daraxonrasib + GnP combination showed 58% confirmed ORR (95% CI: 41, 73) in 40 patients with metastatic PDAC
- Monotherapy arm showed 47% ORR (95% CI: 31, 64), including one complete response
- No Grade 5 treatment-related adverse events reported in either cohort
- Phase 3 RASolute 303 trial ongoing in first-line PDAC; RASolute 302 recently met PFS and OS endpoints
- Pancreatic cancer has ~3% five-year survival rate; >90% of cases harbor RAS mutations
Financial Impact
High potential value creation if Phase 3 trials confirm efficacy, given lack of effective frontline therapies in PDAC and $29B market cap
Risk Factors
- Early-phase data with immature PFS/OS; later-stage results may not confirm benefit
- Competitive landscape could shift with other RAS inhibitors in development
- High market cap reflects significant expectations; any clinical setback could trigger sharp downside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278575 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers